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Dendritic cells (DC) are rare, professional antigen-presenting cells with ability to induce 
or regulate alloimmune responses. Regulatory DC (DCreg) with potential to down-mod-
ulate acute and chronic inflammatory conditions that occur in organ transplantation can 
be generated in  vitro under a variety of conditions. Here, we provide a rationale for 
evaluation of DCreg therapy in clinical organ transplantation with the goal of promoting 
sustained, donor-specific hyporesponsiveness, while lowering the incidence and severity 
of rejection and reducing patients’ dependence on anti-rejection drugs. Generation of 
donor- or recipient-derived DCreg that suppress T cell responses and prolong transplant 
survival in rodents or non-human primates has been well-described. Recently, good 
manufacturing practice (GMP)-grade DCreg have been produced at our Institution for 
prospective use in human organ transplantation. We briefly review experience of regu-
latory immune therapy in organ transplantation and describe our experience generating 
and characterizing human monocyte-derived DCreg. We propose a phase I/II safety 
study in which the influence of donor-derived DCreg combined with conventional immu-
nosuppression on subclinical and clinical rejection and host alloimmune responses will 
be examined in detail.
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iNTRODUCTiON
While rates of acute renal transplant rejection have improved dramatically since the advent of 
calcineurin inhibition (CNI) >30 years ago, similar improvement in long-term graft survival has 
not been achieved. This reflects the inability of conventional immunosuppressive agents to prevent 
late graft dysfunction leading to transplant failure (1, 2). Moreover, conventional immunosuppres-
sion is associated with significant morbidity and mortality due to cardiovascular, infectious, and 
pro-neoplastic side effects. Attempts to improve long-term survival, while reducing the burden of 
immunosuppression, have not been particularly fruitful to date. While the recent introduction of 
co-stimulation blockade, although renal-sparing, has resulted in an increased incidence of acute 
rejection (3), use of depleting antibody (Ab) as induction therapy at the time of transplantation has 
also failed to guarantee safe withdrawal of CNI, even in patients with stable graft function (4, 5). 
Furthermore, efforts to induce donor-specific tolerance using hematopoietic stem cell transplanta-
tion, an approach first shown to be successful many years ago in mice (6), have yielded promising 
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results, but many hurdles remain in terms of safety and wide-
spread applicability (7).
Our long-term goal is to develop a novel, safe, donor-specific 
induction (pre-conditioning) approach that will promote 
sustained, donor-specific immune hyporesponsiveness, while 
lowering the incidence and severity of acute and chronic rejec-
tion and reducing patients’ dependence on anti-rejection drugs. 
There is recent evidence that, by exploiting inherent mechanisms 
of immune regulation, it may be possible to achieve this goal. 
Rare, naturally occurring regulatory immune cells, either innate 
[regulatory dendritic cells (DCreg)] or adaptive [regulatory T 
cells (Treg)], critically regulate immunity, can promote antigen 
(Ag)-specific T cell hyporesponsiveness, and prevent adverse 
immune reactions (self-tolerance) in the healthy steady-state 
(8, 9). Moreover, in small animals, the adoptive transfer of 
DCreg (10–13) or Treg (14) can prolong allograft survival and 
induce donor-specific tolerance to organ transplants (15). Other 
regulatory immune cells with potential therapeutic applications 
include regulatory macrophages [Mreg; (16–18)], myeloid-
derived suppressor cells [MDSC; (19)], T regulatory type-1 
cells [Tr1 cells; (20)], and regulatory B cells (21). In addition to 
ex vivo-expanded Treg, now entering phase I/II trials in organ 
transplantation1, a compelling rationale has emerged for clinical 
testing of DCreg, i.e., donor or recipient blood monocyte-derived 
DC generated and modified ex vivo to promote their inherent 
regulatory properties (13, 22–24). Thus, we and others have 
shown that, in rodents, infusion of DCreg of donor or recipient 
origin before or after transplantation, including their use in 
combination with conventional immunosuppressive agents, can 
promote indefinite organ allograft survival. More importantly 
and uniquely, using a robust, clinically relevant, non-human pri-
mate (NHP) model with minimal immunosuppression, we have 
shown that infusion of donor-derived DCreg, 1  week before 
transplant, safely prolongs major histocompatibility complex 
(MHC)-mismatched, life-sustaining renal allograft survival, 
with no evidence of host sensitization (25). Equally significant is 
our demonstration that this therapeutic effect is associated with 
selective attenuation of donor-reactive memory T cell (Tmem) 
responses (25, 26), an important barrier to improvement of 
long-term graft survival (27, 28).
We have now generated good manufacturing practice 
(GMP) grade human DCreg from elutriated peripheral blood 
monocytes and demonstrated both their stable resistance to 
maturation under inflammatory conditions and their ability 
to negatively regulate alloreactive T cell responses. We have 
also established release criteria for clinical testing and plan to 
conduct a safety trial of donor-derived DCreg in adult, de novo, 
live-donor renal transplantation. To our knowledge, this prom-
ising donor-specific induction approach to regulatory immune 
cell therapy in clinical organ transplantation is unique. It is 
distinct from the testing of recipient blood monocyte-derived 
DCreg in live-donor renal transplantation currently being 
conducted at the University of Nantes, France, as part of The 
ONE Study (29, 30).
1 https://clinicaltrials.gov
THe CASe FOR DCreg THeRAPY iN 
ORGAN TRANSPLANTATiON
Extensive pre-clinical studies that we and others have conducted 
in rodents and human surrogate models provide compelling 
evidence of the potential of regulatory immune cell therapy to 
improve allograft outcomes and, in many instances, promote 
donor-specific tolerance (15). The case for testing DCreg gener-
ated ex vivo in human transplantation is particularly compelling 
(13, 23, 24) for the following reasons. First, DC are uniquely well-
equipped, professional Ag-presenting cells (APC) that potently 
regulate innate and adaptive immunity (31, 32). Second, in many 
animal studies, DCreg adoptively transferred to graft recipients 
before transplant induce Ag-specific T cell unresponsiveness (13) 
and promote indefinite organ allograft survival. Moreover, this 
beneficial effect on graft survival does not appear to depend on the 
in vivo persistence of intact DCreg (33–35). Indeed, the apparent 
independence of efficacy and regulatory mechanisms on the per-
sistence of intact donor DCreg may be a distinct advantage over 
other cell therapy approaches. Thus, e.g., Treg therapy may require 
costly repeated infusion of very large numbers of expanded cells 
(36, 37) and their sustained viability/replication may be required 
to achieve a therapeutic effect. Third, an important attribute of 
DCreg is their ability to regulate, in addition to de novo-primed 
effectors, preformed Tmem responses (38–40) that, either due to 
preformed memory to alloAgs or due to molecular mimicry and 
cross-reactivity with human leukocyte antigens (HLA) (41), rep-
resent a major barrier to long-term graft survival in humans (27, 
28, 42, 43). Fourth, in normal humans, local adoptive transfer of 
monocyte-derived DCreg has been shown to induce Ag-specific 
unresponsiveness to nominal Ags (44, 45). Fifth, using minimal 
immunosuppression in a robust NHP model, we have reported 
that a single infusion (3.5−10 × 106/kg) of donor-derived DCreg, 
1 week before transplant, safely prolongs renal allograft survival, 
with no evidence of host sensitization (25). Importantly, this 
effect is associated with attenuation of donor-specific, alloreactive 
Tmem responses (25, 26).
The unique phase I/II trial of donor-derived DCreg that we 
now propose in live-donor renal transplantation is essentially 
a dose-escalation safety trial in which the cell product will be 
administered, once only, concomitant with mycophenolic acid 
(MPA), 1 week before transplantation to patients receiving stand-
ard immunosuppression (CNI, MPA, and steroids). Successful 
safety evaluation of our strategy and any evidence of inhibition of 
early, acute subclinical or clinical rejection, and/or attenuation of 
long-term anti-donor immunity would justify broader evaluation 
of DCreg efficacy in renal transplantation. This would potentially 
address unmet needs of CNI-free immunosuppression and/or 
realize the unmet goal of improving long-term allograft survival, 
without increasing the burden of immunosuppression.
Thus, in future studies, it would be of interest to evaluate the 
influence of DCreg combined with co-stimulation blockade 
(Co-B) to ascertain whether the incidence of rejection episodes 
encountered with Co-B (3) can be reduced. Furthermore, evi-
dence of a beneficial effect of DCreg pre-conditioning in early 
clinical trials might justify evaluation of immunosuppressive 
drug curtailment. It is likely that the DCreg approach can be 
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applied readily in the clinic since, based on pre-clinical testing, a 
single infusion of a relatively small number of DCreg is sufficient 
to achieve the salutary effect. Therefore, neither expensive expan-
sion of the cell product, nor repeated infusion may be necessary. 
It is also probable that donor-derived DCreg will have broader 
clinical applications to encompass recipients of renal and other 
organ transplants from deceased donors. Indeed, rodent studies 
have shown that delaying DCreg infusion until 7 or 14 days post 
transplant is (still) effective in prolonging graft survival (46, 47), 
thus providing ample time to prepare DCreg from deceased 
donors.
NOveLTY OF THe APPROACH
Several closely interrelated aspects of our proposed clinical trial 
of DCreg in live-donor renal transplantation are highly innova-
tive. First, we have generated a highly-purified GMP cell product 
(allograft donor blood monocyte-derived DCreg) distinct from 
those [autologous tolerogenic DC (not pulsed with donor anti-
gen), Treg, Type-1 regulatory T cells (Tr1) cells, Mreg, and mes-
enchymal stem cells] being investigated by other groups, which 
satisfies phenotypic and functional release criteria. The manu-
facturing process is relatively simple, comparatively short and 
highly reproducible. Second, while early pilot studies have begun 
to examine the safety of autologous DCreg in human autoimmune 
diseases (48–50) and organ transplantation (29), this will be the 
first study to test allogeneic (donor-derived) DCreg in human 
organ transplantation. Third, our proposed mechanistic studies 
will address our hypothesis that, in addition to inhibition of de 
novo T cell priming and memory reactivation against donor HLA 
Ags, DCreg infusion will selectively undermine early inflamma-
tion that fuels anti-donor effector/Tmem responses and promote 
specific T cell unresponsiveness to donor that we will monitor 
sequentially in blood and protocol biopsies. We will also gener-
ate novel insight into the persistence/longevity of donor-derived 
DCreg in graft recipients. Of particular relevance, based on our 
NHP transplant data, will be analyses of de novo-primed T cell 
and Tmem phenotype and function and the potential of establish-
ing new biomarkers of donor-specific hyporesponsiveness based 
on the profile of donor-reactive T cells. Fourth, since protocol 
biopsies will be performed, we will gain preliminary insight into 
the influence of DCreg on the incidence of subclinical rejection, 
an important predictor of long-term graft outcomes by analyzing 
graft-infiltrating T lymphocytes. By contrast, traditional immu-
nosuppression trials have focused on the incidence of clinically 
evident rejection as a principal endpoint.
RATiONALe FOR TeSTiNG DCreg iN 
HUMAN KiDNeY TRANSPLANTATiON
Dendritic cells are highly specialized, bone marrow-derived 
APC [first described >40 year ago (51)] that induce or regulate 
innate and adaptive immunity (13, 32, 52–54). While DCreg 
play a crucial role in maintaining self-tolerance in the healthy 
steady-state (8, 55, 56) over the past 20  year, our research and 
others have revealed that these cells can subvert naïve T cell and 
Tmem responses by various mechanisms (13, 22, 57–59) and that 
DCreg can induce or restore T cell tolerance in animal models of 
autoimmune disease (60–63) or organ transplant rejection (12, 
13, 22, 64). In experimental transplantation, both donor-derived 
allogeneic DCreg and donor Ag-pulsed host autologous DCreg 
are effective. Importantly, our work has also confirmed that 
adoptive transfer of donor-derived DCreg can safely regulate T 
cell responses in clinically relevant NHP models, including MHC 
mis-matched organ allograft recipients (25, 65), an important 
bridge to clinical testing. There is also well-documented evidence 
that adoptive transfer of DCreg (in  vitro-generated autologous 
DC) via local administration can control T cell responses to 
model Ags (flu matrix peptide and keyhole limpet hemacyamin) 
in human healthy volunteers (44, 45). Important insights gained 
from in vitro studies and animal models have driven the recent 
development of clinical grade human DCreg (66–70), with the 
potential to treat autoimmune disease or enhance transplant 
survival, while reducing patients’ dependence on immunosup-
pressive drugs. Phase I safety trials, in which autologous DCreg 
have been administered locally, have been conducted in type-1 
diabetes (48) and rheumatoid arthritis (RA) (49, 50), with results 
that emphasize the feasibility, safety, and potential efficacy of 
DCreg therapy.
Based on these findings, we hypothesize that DCreg infu-
sion, as an adjunct to conventional immunosuppression, can 
improve long-term renal allograft and patient outcomes, with 
minimal early adverse events, by targeting both innate immunity 
and preformed memory responses. It also carries the prospect 
of enabling immunosuppression reduction in stable patients or 
converting to CNI-free immunosuppression, without increasing 
the incidence of rejection.
Our laboratory has had a major focus on the characterization 
and therapeutic efficacy of DCreg, especially in experimental 
pancreatic islet, skin, and organ transplantation (46, 64, 71–79). 
These studies include the first observations that these regula-
tory innate immune cells, deficient in MHC and co-stimulatory 
molecule expression and in the production of pro-inflammatory 
cytokines, could subvert alloAg-specific T cell responses, in vitro 
and in vivo (72, 80). In addition, we have extensive experience 
in the characterization and immune profiling of human T lym-
phocytes, including the contribution of naïve T cell and Tmem 
subsets to the alloimmune response, and the effects of induction 
therapy on regulatory T cell and Tmem subsets in relation to 
clinical outcome in kidney transplantation (41, 81).
eviDeNCe iN SUPPORT OF DCreg 
THeRAPY iN TRANSPLANTATiON
We summarize below evidence from rodent, NHP, and human 
studies that support the safety and, in the case of pre-clinical 
models, the efficacy of DCreg in solid-organ transplantation.
Rodent Observations
We and others have shown that combination of pre-transplant (day 
−7) infusion of donor-derived DCreg, either alone or with low 
doses of immunosuppressive agents, can induce donor-specific 
organ transplant tolerance in rodents (12, 74, 82–85). The route of 
administration, dosage, dosage regimen, and duration of dosing 
TABLe 2 | evidence that use of standard-of-care immunosuppressive 
agents (corticosteroid, MMF, and CNi) together with DCreg promote 
long-term allograft survival in rodents.
Agent Type of allograft 
(species)
Reference
MMF Pancreatic islet (mouse) Adorini et al. (87)
Dexamathasone Renal (rat) Mirenda et al. (84)
Tacrolimus Composite tissue (rat) Eun et al. (88)
Cyclosporine Composite tissue (rat) Ikeguchi et al. (46)
Renal (rat) Mirenda et al. 2004 (84)
MMF, mycophenolate mofetil; CNI, calcineurin inhibitor.
TABLe 1 | Promotion of indefinite heart or renal allograft survival in rodents by infusion of donor-derived DCreg.
DC 
source







MoDC rat GM-CSF i.v. Day + 14/15 None >160 days Hayamizu et al. (86)
BMDC mouse GM-CSF + TGFβ i.v. Day-7 Anti-CD40L mAb >100 days (40%) Lu et al. (73)
BMDC mouse Low GM-CSF i.v. Day-7 None >100 days Lutz et al. (12)
BMDC mouse GM-CSF + IL-4 + NF-κB 
ODN + Ad CTLA4Ig
i.v. Day-7 None >100 days (40%) Bonham et al. (74)
BMDC rat GM-CSF + IL-4 i.v. Day-7 ALS >200 days (50%) DePaz et al. (85)
BMDC mouse Low GM-CSF i.v. Day-7 Anti-CD54 
mAb + CTLA4Ig
>100 days Wang et al. (83)
BMDC Ratb GM-CSF + IL-4 + dexamethasone i.v. Day-10 CTLA4Ig + cyclosporine >100 days Mirenda et al. (84)
aIn relation to transplantation on d0.
bRenal transplant.
Ad, adenoviral vector; ALS, anti-lymphocyte serum; BMDC, bone marrow-derived dendritic cells; i.v., intravenous; MoDC, monocyte-derived DC; MST, mean graft survival time; 
ODN, oligodeoxynucleotides decoys.
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(single i.v. infusion of up to 5 × 106 per kg of donor DCreg, 7 days 
prior to transplantation) that we propose in a phase I clinical trial 
are, therefore, supported by experiments in rodents [Table 1 and 
(12, 73, 74, 82–86)] and NHP (25). It is also important to note that 
use of conventional “standard of care” (SOC) immunosuppressive 
agents (MPA, CNI, or steroids), together with DCreg, promotes 
long-term allograft survival in rodents [Table 2 and (46, 84, 87, 
88)]. This is of direct relevance to the use of SOC immunosup-
pressive therapy in our proposed clinical trial.
NHP Observations
Non-human primate transplant models are considered important 
predictors of the safety and efficacy of experimental immunosup-
pressive/tolerogenic regimens since the NHP immune system 
more closely resembles that of humans than mice, and since, as 
in humans (but not in mice), Tmem present an important and 
difficult to overcome barrier to induction of donor-specific toler-
ance (41, 89–91). We have used a robust, MHC-mismatched, life-
sustaining rhesus macaque renal transplant model to evaluate the 
safety and efficacy of donor-derived DCreg therapy (25). In these 
studies, DCreg were generated from CD14 immunobead-isolated 
blood monocytes in a single leukapheresis product of the prospec-
tive kidney donor in granulocyte macrophage-colony-stimulating 
factor (GM-CSF) and IL-4. During the 7-day culture period, 
vitamin D3 (VitD3), a nuclear factor κβ inhibitor that impairs DC 
differentiation and maturation (92, 93) and IL-10, that converts 
immature DC into tolerogenic APC (94), were added to promote 
the maturation-resistant DCreg phenotype (95). We tested 
whether DCreg of donor origin, infused prospectively (once only) 
7 days before transplant, could safely prolong graft survival using a 
minimal immunosuppressive regimen of co-stimulation blockade 
[CTLA4Ig =  cytotoxic T lymphocyte Ag 4:Ig (abatacept)] and 
mechanistic target of rapamycin (mTOR) inhibition [rapamycin 
(sirolimus)]. Our findings (25) clearly show that (1) no adverse 
effects were encountered, (2) no evidence of host sensitization was 
detected, as determined by circulating anti-donor alloAb levels, (3) 
graft survival time was prolonged significantly (threefold increase) 
in the group given DCreg compared to those recipients that did 
not receive the cell infusion, (4) weight loss and proteinuria were 
less marked in DCreg-infused monkeys, and (5) evidence was 
obtained of significant, donor-specific attenuation (exhaustion) 
of Tmem responses as evidenced by upregulation of concomitant 
programed death (PD)-1 and CTLA4 expression (Figure  1), 
reduced memory:regulatory T cell ratios in peripheral blood, and 
reduced CD8+ effector T cell responses in the transplant (25, 26).
Human Observations
Several pharmacologic agents and cytokines have been used to 
generate GMP grade autologous human DCreg for prospective 
clinical use in chronic inflammatory diseases, including type-1 
diabetes, RA, and multiple sclerosis (48–50, 66–68). The safety 
of locally administered, autologous, monocyte-derived DCreg 
in type-1 diabetes or RA patients has been reported (48–50). 
To our knowledge, there has been no human experience with 
donor-derived DCreg in human organ transplantation. However, 
clinical experience with a closely related, donor-derived myeloid 
lineage cell product in either deceased- or live-donor renal 
transplantation is relevant to the proposed investigation of 
DCreg in organ transplantation. Thus, “immunoregulatory 
macrophages” (Mreg) or “transplant acceptance-inducing cells” 
have been investigated by Hutchinson and colleagues in Germany 
as immune-conditioning therapy in human renal transplantation 
(96). The phenotype of these cells identifies them as a subtype 
of partially mature macrophages (96). Initially, they were gener-
ated from deceased-donor splenic mononuclear cells cultured 
in macrophage (M)-CSF and IFNγ for 5 days and administered 
i.v. on post-transplant day 5. All patients (n = 12; with 3–5 total 
FiGURe 1 | DCreg infusion enhances programed death (PD)-1 and 
cytotoxic T lymphocyte antigen-4 (CTLA4) expression by donor-
reactive CD4+Tmem in renal allograft recipient monkeys. Incidences of 
PD1+ CTLA4+ populations in ex vivo-stimulated CD95+CD4+Tmem from 
representative control and DCreg-treated monkeys (n = 4 monkeys analyzed/
group). Recipient PBMC obtained 28 days after transplantation, were 
co-cultured with either donor or third party stimulators (T cell-depleted 
PBMC) for 5 days before flow cytometric analysis. The enhanced incidence 
of PD1+CTLA4+Tmem in response to donor, but not third party stimulation 
suggests selective attenuation (exhaustion) of donor-reactive Tmem. 
According to Ezzelarab et al. (25), Figure 5.
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MHC-mis-matches) received ≥0.55 × 106 viable Mreg/kg (range 
0.55–7.52 × 106/kg) and were immunosuppressed at the outset 
with tacrolimus, sirolimus, and glucocorticoids. They were then 
weaned from steroid therapy, if clinically appropriate, on day 28 
post-transplant. Administration of comparatively large numbers 
of these cells (up to 5 × 108 viable cells) via a central line was safe, 
with no evidence of graft-versus-host reactions induced by the 
Mreg or contaminating lymphocyte populations. Furthermore, 
as in our NHP DCreg studies, there was no evidence that human 
Mreg sensitized the recipients to donor Ags, or that the cells 
themselves could otherwise accelerate rejection. Importantly, 
none of the study participants experienced any delayed compli-
cations from Mreg infusion (mean follow-up time 36 months). 
Thus, it was concluded that the infusion of (donor-derived) Mreg 
was practicable and safe in the acute and medium term.
The same group of investigators have also infused donor-
derived Mreg to live-donor kidney transplant recipients (n = 5), 
5 days before renal transplantation (97). A larger number of Mreg 
and a different immunosuppressive regimen [anti-thymocyte 
globulin (ATG), tacrolimus, and steroids] were employed. PBMC 
were isolated from donor leukapheresis products 14 days before 
transplant. On day 9 pre-transplant, non-adherent PBMC from 
leukapheresis products of the prospective graft recipients were 
added (2.107/ml) to the donor-derived Mreg and the co-cultures 
of donor origin Mreg and recipient PBMC maintained for a 
further 4 days until infused (1.74−10.39 × 107 Mreg/kg) 5 days 
before transplant. No complications were observed. Moreover, 
there was no evidence that infusion of donor-derived Mreg 
prior to transplantation could sensitize recipients to donor Ags 
or otherwise accelerate graft rejection. As in the earlier study, it 
was concluded that preoperative treatment of live-donor kidney 
transplant recipients with Mreg was clinically practicable and safe 
in the acute and medium term.
In a further (2011) publication (98), the same group (plus 
additional authors) reported on two live-donor renal transplant 
patients who were given donor-derived Mreg (99) cultured for 
6 days with M-CSF before stimulation with IFNγ for a further 
24  h, and then administered 6 or 7  days before transplant. In 
this case, the Mreg were CD14−/lo, HLA-DR+, CD30−/lo, CD86+, 
CD16−, toll-like receptor (TLR)2−, and CD163−/lo. One patient 
(single HLA-B and HLA-DR mismatches) received 8.0 ×  106 
cells/kg and the other (fully HLA-mismatched) received 
7.1 × 106 cells/kg. Labeling of a proportion of the infused Mreg 
with [111In]-oxine in one patient and whole-body single photon 
emission computed tomography imaging (SPECT) revealed 
that the Mreg located initially in the lungs, but after 2.5 h were 
evident in the circulation and had begun to accumulate in the 
liver and spleen. Twenty-four hours after Mreg infusion, signal 
from the lung had diminished substantially and the cells had 
accumulated in the liver, spleen, and bone marrow. Absence 
of signal from the patient’s urinary tract throughout the 30  h 
follow-up suggested that the majority of labeled infused cells 
remained alive. No unexpected adverse events were observed 
in either patient. At 3 and 2 year, respectively, post-transplant, 
the patients were taking once-daily or twice-weekly tacrolimus. 
Despite early minimization of immunosuppressive therapy, 
neither patient underwent an acute rejection episode during the 
3-year follow-up period.
POTeNTiAL MeCHANiSMS OF THe 
LONG-TeRM MAiNTeNANCe OF 
SUPPReSSiON AFTeR DCreg 
ADMiNiSTRATiON
The in vivo mechanisms whereby infusion of donor (or recipient)-
derived DCreg restrains alloimmunity and promotes long-term 
survival of experimental organ allografts are not well understood. 
In mice, there is evidence that donor-derived DCreg infused 
before transplantation are targeted by host NK cells and, thus, 
short-lived (35). They are reprocessed by quiescent host splenic 
DCs for presentation of alloAg to indirect pathway CD4+ T cells. 
This results in abortive activation and deletion of T effector cells 
without impairing the incidence of indirect CD4+ Foxp3+ Treg, 
thus enhancing the regulatory to effector T cell ratio (33, 100). It 
appears, therefore, that mechanisms that sustain long-term graft 
survival are not dependent on persistence of intact donor DCreg.
PROPOSeD CLiNiCAL TeSTiNG OF DCreg 
iN ReNAL TRANSPLANTATiON
Here, we propose a protocol for the generation and testing of 
donor-derived DCreg in a phase I clinical trial in renal transplant 
recipients receiving conventional immunosuppressive therapy.
Generation, Purity, and Yield of hu DCreg
To ensure sufficient DCreg yields, blood monocytes will 
be obtained and banked in high purity by elutriation from 
FiGURe 2 | Generation of DCreg from elutriated blood monocytes of 
the prospective renal allograft donor in GM-CSF, vitD3, and iL-10, and 
infusion of the validated cell product into the graft recipient 7 days 
before transplant.
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cryopreserved leukapheresis products of the prospective 
transplant donors approximately 28–15  days before scheduled 
transplantation (Figure 2). Fourteen days before transplantation, 
monocytes will be thawed and DCreg generated for infusion 
into the prospective graft recipient on day-7 (Figure 1). In our 
experience, whole individual leukapheresis products from non-
mobilized, healthy adult volunteers yield 4.3 ± 1.05 × 109 PBMC. 
Recovery of monocytes post-elutriation [consistently ≥90% pure 
with <1% CD3+ T cell contamination (n =  4)] represents, on 
average, 25% of the total PBMC. The phenotype of the purified 
monocytes, determined by flow cytometry, is HLA-DR+ CD40lo 
CD80lo CD86+, programed death ligand (PD-L) 1lo, CD14+.
The DCreg are generated from thawed monocytes in serum-
free Cell Genix (Cellgro) medium, supplemented with 5% certi-
fied human AB serum and recombinant human (rhu) GM-CSF 
(1000 units/ml) and rhu IL-4. These cytokines are added at the 
start of culture (day 0) and on day 4. VitD3 and rhu IL-10, which 
suppress DC maturation (94, 101, 102), are also added on day 
4. The culture period is 7  days. We consistently generate suf-
ficient, highly purified DCreg from elutriated peripheral blood 
monocytes (yield  =  17  ±  7% of starting monocyte number) 
from a single whole leukapheresis product to administer up to 
2.0−2.5 × 106 per kg to a 70 kg recipient. To obtain larger numbers 
of DCreg for a higher dose, a second donor leukapheresis may 
be required.
The DCreg harvested at day 7 of culture are consistently 
>94% pure, with ≤0.1% contaminating CD3+T lymphocytes 
determined by flow cytometry. It is especially significant that 
the incidence of T cells is so low since these are the cells that 
are of concern regarding risk of graft-versus-host disease. The 
DCreg consistently exhibit an immature phenotype compared to 
control DC (i.e., immature DC generated in DC media without 
VitD3 and IL-10) and are HLA-DR+, CD11c+, CD14−, CD40lo, 
CD80lo, CD86lo, PD-L1hi, CCR7+, CD83lo. High expression of 
PD-L1(=  B7-H1), a negative regulator of T cell responses and 
a consistently high PD-L1:CD86 ratio [determined as: PD-L1 
mean fluorescence intensity (MFI) ÷ isotype control/CD86 (MFI) 
÷ isotype control] conforms to that of DCreg with potential to 
subvert alloreactive T cell responses.
Function of DCreg
Investigation of the function of hu DCreg harvested at 7 days of 
culture, including their responses to the TLR4 ligand bacterial 
lipopolysaccharide (LPS), CD40 ligation, or a pro-inflammatory 
cytokine cocktail, will ensure their regulatory properties. The 
DCreg we have generated display robust resistance to phenotypic 
and functional maturation in response to factors that promote 
the maturation of control DC, confirming that they are refractory 
to stimulation under inflammatory conditions. In particular, the 
inability of DCreg exposed to LPS to release pro-inflammatory 
and immunostimulatory cytokines (tumor necrosis factor 
[TNF]α and IL-12p70) is profoundly inhibited, while production 
of anti-inflammatory IL-10 is preserved, resulting in marked 
reversal of the IL-12:IL-10 and TNFα:IL-10 ratios.
The ability of the DCreg exposed to LPS to induce hypore-
sponsiveness of normal allogeneic T cells is of paramount impor-
tance. Therefore, DCreg (ratio 1 DCreg:40 T cells) should induce 
minimal CD4 and CD8 T cell proliferation, IFNγ and IL-17 
release, or granzyme B production in the responder CD4+ T cells 
over 4 days in culture. This analysis provides further assurance 
of the inability of the DCreg, despite exposure to a potent pro-
inflammatory stimulus (LPS), to stimulate allogeneic effector T 
cell responses. Similarly, marked attenuation of alloreactive CD8+ 
T cell responses is observed.
Thus, we contend that infusion of DCreg that are (1) phenotypi-
cally immature, (2) resistant to maturation under inflammatory 
conditions, and (3) able to induce allogeneic T cell hyporespon-
siveness in  vitro will not induce sensitization of prospective 
recipients following their adoptive in vivo cell transfer and rather, 
will induce donor-specific T cell hyporesponsiveness. Our plan 
to closely monitor study patients for evidence of development of 
donor-specific alloAb production and anti-donor T cell reactivity 
will allow detection of any increase in anti-donor immune effec-
tor activity in the unlikely event it should occur.
Release Criteria for DCreg
The DCreg generated for infusion will undergo rigorous testing 
at specified time points during their manufacture from blood 
monocytes. The following release criteria will be considered as 
crucially important: DCreg yield (sufficient cells to allow infu-
sion of the target number per kilogram), percent purity (>95% 
DC, <1% T cells), and viability (>70%); sterility; DCreg phe-
notype: phenotypic characterization will be performed by flow 
cytometry to monitor CD86 and PD-L1 expression before and 
after LPS stimulation, compared to conventional DC cultured 
in GM-CSF +  IL-4 and not VitD3 and IL-10. High PD-L1 and 
low CD86 expression, before and after LPS stimulation, with a 
PD-L1:CD86 ratio >3.5 (based on pre-clinical results) will be 
used as a release criterion. The 3.5 ratio is based on many analyses 
in which a ratio of 3.5 or above was associated with a cytokine 
profile and T cell stimulatory profile consistent with the induc-
tion of alloreactive T cell hyporesponsiveness. DCreg function: 
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supernatants from cultures (DCreg exposed or not to LPS) will 
be tested by ELISA to assess the lack of IL-12p70/TNF-α and the 
presence of IL-10 production, consistent with their regulatory 
properties and their resistance to maturation. We consider this, 
in addition to the tests above, a simple, reproducible, release 
criterion that can be applied before release of the DCreg product 
for infusion.
DCreg infusion
We plan to test three dose levels of DCreg in three separate groups 
of recipients (n = 5/group, with 4 receiving DCreg and 1 “control” 
subject receiving concomitant pre- and post-transplant immu-
nosuppression without DCreg): dose 1: 0.5 × 106 cells/kg body 
weight; dose 2: 2.5 × 106 cells/kg body weight; dose 3: 5 × 106 
cells/kg body weight.
Concurrent immunosuppressive Drug 
Regimen
The renal transplant recipients will receive combination immuno-
suppressive medications according to SOC at our Institute, with 
two exceptions. First, MPA (that blocks DNA synthesis in T and B 
cells) will be initiated 7 days before transplant, at the time of donor 
DCreg infusion, instead of on the day of transplantation. This is in 
order to minimize any risk of sensitizing the patient. Historically, 
pre-treatment of kidney transplant recipients with unmodified 
donor-specific transfusions and low-dose azathioprine (that acts 
similarly to MPA) significantly reduced the risk of sensitization 
(103–107). Furthermore, MPA augments and maintains the 
regulatory function of DC (108, 109), additionally minimizing 
any safety concern that DCreg could convert to a stimulatory 
phenotype after infusion. Second, Ab induction therapy will 
not be administered at the time of transplant. Patients will be 
maintained on triple immunosuppressive therapy with MPA, 
tacrolimus, and prednisone after transplantation, a combination 
regimen widely applied as SOC at many transplant centers, both 
in North America and elsewhere worldwide and in The ONE 
Study of regulatory immune cell therapy in renal transplantation2, 
a trans-Atlantic (European and North American) trial utilizing 
a unified approach to evaluating immune cell therapy in renal 
transplantation for the reasons outlined above. The immunosup-
pressive drug regimen that we propose differs from the regimen 
(belatacept and rapamycin) that we used together with DCreg 
in NHP (25). This is because belatacept plus rapamycin is not 
SOC in human renal transplantation and it is important to assess 
the safety and efficacy of DCreg in humans in comparison with 
current SOC, as being evaluated in The ONE study, including the 
testing of autologous DCreg.
The rationale for not using ATG, alemtuzumab (anti-CD52 
mAb) or basiliximab (anti-IL-2Rα mAb) as induction therapy 
at transplant, is to avoid potential targeting of DCreg infused 
7  days before transplant or dampening of immunoregulatory 
pathways triggered in host T cells by DCreg. In our NHP study, 
we established that such an approach (pre-transplant immu-
nosuppression at the time of DCreg infusion and avoidance of 
2 http://www.onestudy.org
lymphocyte-depleting induction agents) is both safe and effec-
tive. We have opted, however, not to use a Co-B and/or mTOR 
inhibition-based immunosuppressive regimen, such as that 
employed in our NHP study, because of the high incidence of 
acute rejection episodes, including higher grade rejection, in 
patients receiving Co-B (belatacept), MPA, and steroid therapy 
and increased side effects in clinical trials of rapamycin-based 
regimens, either with CNI or MPA (3, 5). Since our initial pro-
posed clinical trial is a safety trial, we have chosen to adhere to 
a safe and proven immunosuppression regimen that does not 
interfere with DCreg action.
Persistence of Donor DCreg after infusion
Monitoring DCreg persistence in the circulation and their tis-
sue homing is essential for understanding their survival and 
distribution. Flow cytometry techniques to detect donor T cells 
in peripheral blood of transplant recipients with a threshold sen-
sitivity of one donor cell in 1000 recipient cells (0.1%) are readily 
available (110). We plan to identify donor DCreg in whole blood 
at various time points post-transplant, by flow staining for Lin−, 
HLA-DR+, BDCA1(CD1c)+, CD209 (DC SIGN)+, CD11c+ DC, 
in conjunction with staining for a miss-matched donor MHC 
allele. This approach will allow us distinguish between recipient 
and donor-derived DCreg. Others (98) have used [111In]-oxine 
to label allogeneic donor-derived myeloid cells (Mreg) for 
short-term tracking by SPECT imaging following their infusion 
in renal transplant patients and we will consider using this as a 
complementary approach.
Mechanistic and immunological 
Monitoring Analyses of Transplant 
Recipients
Cellular pathways engaged after organ transplantation are com-
plex and involve coordinated interactions between DC as APC 
and distinct effector and regulatory T cell subsets, which can lead 
to a state of Ag-cognate effector cell hyporesponsiveness (graft 
acceptance or quiescence). While it is believed that DCreg are 
effective in blunting Tmem responses (25, 38–40) and de novo-
primed naive T cells (13, 34), it is unclear how long after infu-
sion donor-derived DCreg persist in the peripheral blood or in 
lymphoid tissue of transplant patients, and which mechanism(s) 
(clonal deletion, anergy, regulation, or exhaustion) may contrib-
ute to inducing donor-specific T cell hyporesponsiveness. Our 
hypothesis is that infusion of donor-derived DCreg (even if their 
survival is short-lived) (35) will induce donor-specific T cell 
hyporesponsiveness in the recipient, while nominal T cell recall 
responses [such as those to anti-Epstein–Barr virus (EBV) or 
tetanus toxoid (TT)] will be preserved. This could be mediated 
by decreased donor allo-specific Tmem frequencies and result 
in residual low allo-specific Tmem proliferation, IFN-γ and 
Granzyme B/Perforin production in response to donor Ag stimu-
lation, but with preserved responses to EBV and TT stimulation.
To address these questions, we will collect blood samples 
pre-transplant on day −7 (pre DCreg infusion), on day 0, and 
at 3 months, 1 year, and 2 year post-transplant. We will (1) char-
acterize the phenotype, memory differentiation, and function of 
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different T cell subsets, (2) assess donor-reactive T cell clonality 
and function, (3) identify effector and regulatory cells and mol-
ecules in for-cause and protocol biopsy samples. While no single 
immunologic test can identify peripheral hyporesponsiveness 
after organ transplantation, we will attempt to assess multiple 
essential T cell immune parameters methodically at the same 
time, an approach expected to provide a possible signature and 
mechanism of peripheral anti-donor hyporesponsiveness after 
DCreg infusion.
We will assess T cell expression of co-stimulatory receptors 
[e.g., CD28, inducible costimulator (ICOS) and CD40L], which 
are critical for cross-talk with DC, as well as co-inhibitory recep-
tors [PD-1, TIM3 (T cell immunoglobulin mucin domain 3) and 
cytotoxic T lymphocyte Ag (CTLA)-4] that are up-regulated on 
recently activated/exhausted T cells in conjunction with expres-
sion of Annexin V/7-AAD to track apoptosis. We will also track 
EBV-specific and anti-TT T cells as controls for recall responses. 
We will correlate the levels of memory CD8+, CD4+ TFH, and 
CD4+ Tconv effectors with Treg, DSA titer, plasma cytokines 
and effector and regulatory cell, IgG, and complement (C4d) 
deposition in the allograft. Age-matched healthy controls and 
renal transplant patients who did not receive DCreg infusion will 
serve as controls.
CONCLUSiON
There is extensive evidence that DCreg of donor origin can 
regulate alloimmune responses and promote long-term organ 
transplant survival in rodents. The recent observation that 
DCreg can safely prolong renal transplant survival in a robust, 
pre-clinical NHP model, in which the graft recipients received a 
minimal immunosuppressive regimen, provides further justifica-
tion for a clinical trial. Appropriate culture conditions, leading 
to the manufacture of GMP grade DCreg, which are resistant 
to maturation and have potential to regulate host alloimmunity, 
have been developed for clinical testing.
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